Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic
  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Names Four New Members to Executive Team

Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), has announced that four new executives will be joining the company’s management team. The four new leaders include Mark White as chief business officer; Alexander Morris, PhD, as director of strategic communications; Hilda Maibach as senior vice president of statistics; and Blake Jensen as head of quality. White is currently serving as a board member and has held positions of increasing responsibility at Pfizer, Bracco, Abbott and Bayer. Most recently, he was vice president of worldwide marketing at Pfizer, where he led global new product development, business development and in-line marketing for the Inflammation Therapeutic Area. Morin has garnered impressive experience in the science and communications space, specifically in the biopharmaceutical industry. He has served as an account executive at a boutique public relations firm, managing corporate communications strategies for a diverse range of clients, including early-to-late stage biotech companies, nonprofit organizations and large pharma clients. He also has rich experience as a consultant scientist. With more than three decades of experience in all aspects of clinical and observational studies in oncology, infectious disease, metabolic disorders and central nervous system disorders, Maibach brings invaluable expertise to the Annovis team. She has a background in supporting clinical trials with a focus on improving measurement sensitivity and innovating clinical trial design, data acquisition and management. She also has a keen sense of how to incorporate real-world evidence along with bioinformatics tools into clinical study design management to reduce costs and improve outcome reliability. Jensen has two decades of experience with contract service providers and emerging biopharma companies; he has also served as an investigator for the U.S. Food and Drug Administration. His expertise includes designing, building and implementing quality systems from scratch. He has facilitated teams across an array of sectors, including quality-risk management, global audits, vendor management, audit and inspection defense, policy and procedure management, billable audits and quality analytics. “We are delighted to have this strong group of individuals join the Annovis team,” said Annovis Bio founder, president and CEO Maria Maccecchini, PhD., in the press release. “Their expertise and leadership are critical in this pivotal moment in our company, as we continue making strides towards bringing buntanetap closer to NDA and to market for Alzheimer’s and Parkinson’s diseases.”

To view the full press release, visit https://ibn.fm/5pNSR

About Annovis Bio Inc.

Annovis Bio is headquartered in Malvern, Pennsylvania, and is dedicated to addressing neurodegeneration in diseases such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”). The company’s innovative approach targets multiple neurotoxic proteins, aiming to restore brain function and improve the quality of life for patients. For more information about the company, visit www.AnnovisBio.com.

For more information, visit the company’s website at www.AnnovisBio.com, and social channels LinkedIn, X and YouTube.

NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.